目的探討高強(qiáng)度聚焦超聲治療對(duì)肝癌細(xì)胞血道播散的影響。方法應(yīng)用NestedRTPCR技術(shù)檢測(cè)19例患者高強(qiáng)度聚焦超聲治療前、后外周血AFP mRNA的表達(dá)，觀察其對(duì)肝癌細(xì)胞血道播散的影響。結(jié)果①高強(qiáng)度聚焦超聲治療前，19例肝癌患者外周血檢出AFP mRNA表達(dá)者11例（57.9%），良性疾病對(duì)照組均未檢出。治療前AFP mRNA表達(dá)陽(yáng)性率與血清AFP水平、腫瘤直徑、門靜脈癌栓、遠(yuǎn)處轉(zhuǎn)移等臨床參數(shù)明顯相關(guān)(P＜0.05)。②余8例治療前AFP mRNA表達(dá)陰性者，有2例于術(shù)后即刻轉(zhuǎn)為陽(yáng)性，其中1例于72 h后又復(fù)轉(zhuǎn)為陰性； 19例患者于治療后1周時(shí)其AFP mRNA表達(dá)陽(yáng)性率（31.6%）低于治療前，但差異無(wú)統(tǒng)計(jì)學(xué)意義（P gt;0.05）。③治療后1周時(shí)，腫瘤直徑≤8 cm者AFP mRNA表達(dá)陽(yáng)性率低于直徑 gt;8 cm者(P＜0.05)。結(jié)論高強(qiáng)度聚焦超聲治療可能會(huì)降低肝癌的血道播散，特別是對(duì)于腫瘤直徑≤8 cm的肝癌患者，療效較好。
引用本文： 李富宇,劉紅,龍泉伊,蔣力生,許瑞華. 高強(qiáng)度聚焦超聲治療對(duì)肝癌患者外周血AFP mRNA的影響. 中國(guó)普外基礎(chǔ)與臨床雜志, 2004, 11(3): 247-249. doi: 復(fù)制
| 1. | Farmer DG, Rosove MH, Shaked A, et al. Current treatment modalities for hepatocellular carcinoma [Ｊ]. Ann Surg, 1994; 219(3)∶ 236. |
| 2. | Yang R, Reilly CR, Rescorla FJ, et al. Highintensity focused ultrasound in the treatment of experimental liver cancer [Ｊ]. Arch Surg, 1991; 126(8)∶1002. |
| 3. | Oosterhof GO, Cornel EB, Smits GA, et al. Influence of highintensity focused ultrasound on the development of metastases [Ｊ]. Eur Urol, 1997; 32(1)∶91. |
| 4. | Komeda T, Fukuda Y, Sando T, et al. Sensitive detection of circulating hepatocellular carcinoma cells in peripheral venous blood [Ｊ]. Cancer, 1995; 75(9)∶2214. |
| 5. | Wang L, Tang ZY, Qin LX, et al. Highdose and longterm therapy with interferonalfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential [Ｊ]. Hepatology, 2000; 32(1)∶43. |
| 6. | Matsumura M, Niwa Y, Kato N, et al. Detection of alphafetoprotein mRNA, an indicator of hematogenous spreading hepatocellular carcinoma, in the circulation: a possible predictor of metastatic hepatocellular carcinoma [Ｊ]. Hepatology, 1994; 20(6)∶1418. |
| 7. | Prat F, Centarti M, Sibille A, et al. Extracorporeal highintensity focused ultrasound for VX2 liver tumors in the rabbit [Ｊ]. Hepatology, 1995; 21(3)∶832. |
- 1. Farmer DG, Rosove MH, Shaked A, et al. Current treatment modalities for hepatocellular carcinoma [Ｊ]. Ann Surg, 1994; 219(3)∶ 236.
- 2. Yang R, Reilly CR, Rescorla FJ, et al. Highintensity focused ultrasound in the treatment of experimental liver cancer [Ｊ]. Arch Surg, 1991; 126(8)∶1002.
- 3. Oosterhof GO, Cornel EB, Smits GA, et al. Influence of highintensity focused ultrasound on the development of metastases [Ｊ]. Eur Urol, 1997; 32(1)∶91.
- 4. Komeda T, Fukuda Y, Sando T, et al. Sensitive detection of circulating hepatocellular carcinoma cells in peripheral venous blood [Ｊ]. Cancer, 1995; 75(9)∶2214.
- 5. Wang L, Tang ZY, Qin LX, et al. Highdose and longterm therapy with interferonalfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential [Ｊ]. Hepatology, 2000; 32(1)∶43.
- 6. Matsumura M, Niwa Y, Kato N, et al. Detection of alphafetoprotein mRNA, an indicator of hematogenous spreading hepatocellular carcinoma, in the circulation: a possible predictor of metastatic hepatocellular carcinoma [Ｊ]. Hepatology, 1994; 20(6)∶1418.
- 7. Prat F, Centarti M, Sibille A, et al. Extracorporeal highintensity focused ultrasound for VX2 liver tumors in the rabbit [Ｊ]. Hepatology, 1995; 21(3)∶832.